Compare CSPI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | AARD |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.6M | 85.7M |
| IPO Year | 1994 | N/A |
| Metric | CSPI | AARD |
|---|---|---|
| Price | $8.49 | $4.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 27.6K | ★ 128.7K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $219.00 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.55 | $3.35 |
| 52 Week High | $15.00 | $17.94 |
| Indicator | CSPI | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 56.69 |
| Support Level | $7.98 | $3.38 |
| Resistance Level | $9.31 | $6.01 |
| Average True Range (ATR) | 0.69 | 0.40 |
| MACD | -0.04 | 0.19 |
| Stochastic Oscillator | 19.14 | 60.80 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.